Bioengineered Protein Drugs Market 2024-2033: Growth Trends, Forecast & Competitive Landscape

The bioengineered protein drugs market size has grown strongly in recent years. It will grow from $379.36 billion in 2023 to $411.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased understanding of diseases, regulatory approvals, rising prevalence of chronic diseases, collaborations and partnership, market expansion.

The bioengineered protein drugs market size is expected to see strong growth in the next few years. It will grow to $556.9 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to personalized medicine trends, expanding therapeutic applications, emerging markets, focus on rare diseases, healthcare infrastructure development. Major trends in the forecast period include advancements in protein engineering, increased focus on monoclonal antibodies, personalized medicine and targeted therapies, emergence of next-generation biologics, manufacturing process optimization.

Market Overview -
Bioengineered protein drugs are defined as drugs that are manufactured through certain laboratory techniques using living cells, which include applications of biological processes and protein molecules. The use of bioengineered proteins allows for the tuning of mechanical and stimuli-sensitive qualities, together with high purity and uniform molecular weight, avoiding adverse results.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=10180&type=smp

Rising Chronic Disease Prevalence Propels Expansion Of Bioengineered Protein Drug Market
The increasing prevalence of chronic disease is expected to propel the growth of the bioengineered protein drug market going forward. Chronic diseases refer to those diseases from which people suffer for a year or longer, require continuous medical care, and restrict everyday physical activities. Bioengineered protein drugs are used for the treatment of chronic diseases with designer protein therapies for use in oncology and regenerative medicine using combinatorial and logical methodologies. For instance, in September 2022, according to the World Health Organization (WHO) 2022 Highlights, a Switzerland-based intergovernmental health organization, there were 41 million deaths, which is 74% of those caused by noncommunicable diseases (NCDs) or chronic diseases every year globally were 17.9 million deaths are from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths are from diabetes. Therefore, increasing chronic disease is driving the growth of bioengineered protein drugs.

Competitive Landscape -
Major companies operating in the bioengineered protein drugs market report are Abbvie Inc., Amgen Inc., Astrazeneca PLC, Bayer HealthCare Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Sanofi S.A., Grifols S.A., Adma Biologics Inc., CSL Limited, Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Merck & Co. Inc., Pfizer Inc., Biogen Inc., Bristol-Myers Squibb Company, Genentech Inc., Lonza Group AG, MedImmune LLC, Regeneron Pharmaceuticals Inc., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shanghai United Cell Biotechnology Co. Ltd., Panacea Biotec Ltd.

Product Innovations Drive Progress In The Bioengineered Protein Drug Market
Product innovations are a key trend gaining popularity in the bioengineered protein drug market. Companies operating in the bioengineered protein drug market are adopting new technologies to sustain their position in the market. For instance, in July 2021, Janssen Pharmaceuticals, Inc., a Belgium-based pharmaceutical company, launched RYBREVANT, a Food and Drug Administration (FDA)-approved bioengineered protein drug. Rybrevant (amivantamab-vmjw) is a monoclonal antibody drug that is used to treat non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The technology used in the development of Rybrevant is a combination of molecular biology, cell culture, and protein engineering techniques. Rybrevant was developed using a phage display process, in which a library of antibodies is screened for those that bind specifically to the target protein.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/bioengineered-protein-drugs-global-market-report

Key Segments -
The bioengineered protein drugs market covered in this report is segmented -
1) By Drug Type: Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes, Other Drug Type
2) By Technology: Bioreactors, Fractionation, Genetically Modified Organisms, Genetic Engineering, Pharming, Cell Culture, Microbial Cell Fermentation, Other Technology
3) By Application: Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis, Other Application
4) By End User: Pharmaceutical, Contract Research Organizations, Research Institutes, Biotechnology Companies

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.